Incidence of Infection is Inversely Related to Steady-State (Trough) Serum IgG Level in Studies of Subcutaneous IgG in PIDD

被引：30

作者：

Berger, Melvin ^{[1
]}

机构：

[1] CSL Behring LLC, King Of Prussia, PA 19406 USA

来源：

JOURNAL OF CLINICAL IMMUNOLOGY | 2011年 / 31卷 / 05期

关键词：

Immunodeficiency; infection; subcutaneous; immunoglobulin; PRIMARY IMMUNODEFICIENCY DISEASES; IMMUNOGLOBULIN; SAFETY; EFFICACY; PHARMACOKINETICS; REPLACEMENT;

D O I：

10.1007/s10875-011-9546-2

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Results from seven studies of four subcutaneous IgG preparations in patients with primary immune deficiencies show that the incidence of infection is inversely related to the steady-state IgG level. Maintaining higher IgG levels may be beneficial, and no given level is necessarily adequate for all patients.

引用

收藏

页码：924 / 926

页数：3

相关论文

共 19 条

[1] Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies [J].

Berger, Melvin ;

Rojavin, Mikhail ;

Kiessling, Peter ;

Zenker, Othmar .

CLINICAL IMMUNOLOGY, 2011, 139 (02) :133-141

[2] Improved Quality of Life, Immunoglobulin G Levels, and Infection Rates in Patients with Primary Immunodeficiency Diseases during Self-Treatment with Subcutaneous Immunoglobulin G [J].

Berger, Melvin ;

Murphy, Elyse ;

Riley, Patty ;

Bergman, Garrett E. .

SOUTHERN MEDICAL JOURNAL, 2010, 103 (09) :856-863

[3] Subcutaneous Administration of IgG [J].

Berger, Melvin .

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2008, 28 (04) :779-802

[4] Self-infusion Programmes for Immunoglobulin Replacement at Home: Feasibility, Safety and Efficacy [J].

Bhole, Malini V. ;

Burton, Janet ;

Chapel, Helen M. .

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2008, 28 (04) :821-832

[5] Biologic IgG level in primary immunodeficiency disease: The IgG level that protects against recurrent infection [J].

Bonagura, Vincent R. ;

Marchlewski, Robert ;

Cox, Amanda ;

Rosenthal, David W. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 122 (01) :210-212

[6] Pharmacokinetics of Immunoglobulin Administered via Intravenous or Subcutaneous Routes [J].

Bonilla, Francisco A. .

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2008, 28 (04) :803-819

[7] A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously [J].

Desai, Shilpa H. ;

Chouksey, Akhil ;

Poll, John ;

Berger, Melvin .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 124 (04) :854-856

[8] Immunoglobulin treatment for primary antibody deficiencies - Advantages of the subcutaneous route [J].

Gardulf, Ann .

BIODRUGS, 2007, 21 (02) :105-116

[9] Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies -: A prospective, multi-national study [J].

Gardulf, Ann ;

Nicolay, Uwe ;

Asensio, Oscar ;

Bernatowska, Ewa ;

Boeck, Andreas ;

Costa Carvalho, Beatriz ;

Granert, Carl ;

Haag, Stefan ;

Hernandez, Dolores ;

Kiessling, Peter ;

Kus, Jan ;

Pons, Jaune ;

Niehues, Tim ;

Schmidt, Sigune ;

Schulze, Ilka ;

Borte, Michael .

JOURNAL OF CLINICAL IMMUNOLOGY, 2006, 26 (02) :177-185

[10] Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency [J].

Hagan, John B. ;

Fasano, Mary B. ;

Spector, Sheldon ;

Wasserman, Richard L. ;

Melamed, Isaac ;

Rojavin, Mikhail A. ;

Zenker, Othmar ;

Orange, Jordan S. .

JOURNAL OF CLINICAL IMMUNOLOGY, 2010, 30 (05) :734-745